泰德医药(03880)发盈警预计上半年利润同比减少约44%至51.6%

智通财经

Jul 31

智通财经APP讯，泰德医药(03880)发布公告，相较于截至2025年6月30日止六个月的数据，董事会预期截至2026年6月30日止六个月：1.收入将介于约人民币2.298亿元至2.392亿元，同比减少约5.7%至9.4%;2.利润将介于约人民币4940万元至5710万元，同比减少约44.0%至51.6%;3.经调整净利润(非国际财务报告准则计量)将介于约人民币5140万元至5930万元，同比减少约43.1%至50.6%。

该等业绩变动主要归因于以下综合因素的影响：1.收入确认的时间性差异：部分客户订单的交付及收入确认预计将延迟至2026年下半年，导致中期收入阶段性减少。2.利润下降的主要原因：(i)集团若干现金及现金等价物以及贸易应收款项以美元计价。期内人民币升值导致账面取得外汇损失，对利润产生负面影响;(ii)非经常性收益消失：2025年中期利润包含一笔因赎回负债于公司上市时转换为权益而产生的以公允价值计入损益的金融负债的公允价值变动所产生的非经常性收益。此乃一次性项目，于2026年中期不再发生;(iii)销售收入同比下降，导致毛利额下降。

董事会谨此强调，上述中期业绩波动并未影响集团的核心业务实力及长期发展前景。随着与客户的合作持续深化及其管线进展，集团于2026年7月成功获得海外客户一笔大额订单。该订单强化了集团的订单储备。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2655356079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655356079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655356079?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-31 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655356079","market":"us","top_or_hot":-1,"title":"泰德医药(03880)发盈警 预计上半年利润同比减少约44%至51.6%","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/03880\">泰德医药</a>(03880)发布公告，相较于截至2025年6月30日止六个月的数据，董事会预期截至2026年6月30日止六个月：1.收入将介于约人民币2.298亿元至2.392亿元，同比减少约5.7%至9.4%;2.利润将介于约人民币4940万元至5710万元，同比减少约44.0%至51.6%;3.经调整净利润(非国际财务报告准则计量)将介于约人民币5140万元至5930万元，同比减少约43.1%至50.6%。</p><p>该等业绩变动主要归因于以下综合因素的影响：1.收入确认的时间性差异：部分客户订单的交付及收入确认预计将延迟至2026年下半年，导致中期收入阶段性减少。2.利润下降的主要原因：(i)集团若干现金及现金等价物以及贸易应收款项以美元计价。期内人民币升值导致账面取得外汇损失，对利润产生负面影响;(ii)非经常性收益消失：2025年中期利润包含一笔因赎回负债于公司上市时转换为权益而产生的以公允价值计入损益的金融负债的公允价值变动所产生的非经常性收益。此乃一次性项目，于2026年中期不再发生;(iii)销售收入同比下降，导致毛利额下降。</p><p>董事会谨此强调，上述中期业绩波动并未影响集团的核心业务实力及长期发展前景。随着与客户的合作持续深化及其管线进展，集团于2026年7月成功获得海外客户一笔大额订单。该订单强化了集团的订单储备。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>泰德医药(03880)发盈警 预计上半年利润同比减少约44%至51.6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n泰德医药(03880)发盈警 预计上半年利润同比减少约44%至51.6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 16:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1474591.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，泰德医药(03880)发布公告，相较于截至2025年6月30日止六个月的数据，董事会预期截至2026年6月30日止六个月：1.收入将介于约人民币2.298亿元至2.392亿元，同比减少约5.7%至9.4%;2.利润将介于约人民币4940万元至5710万元，同比减少约44.0%至51.6%;3.经调整净利润(非国际财务报告准则计量)将介于约人民币5140万元至5930万元，同比减少...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1474591.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1474591.html","article_id":"2655356079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655356079","pubTimestamp":1785487130,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，泰德医药 发布公告，相较于截至2025年6月30日止六个月的数据，董事会预期截至2026年6月30日止六个月：1.收入将介于约人民币2.298亿元至2.392亿元，同比减少约5.7%至9.4%;2.利润将介于约人民币4940万元至5710万元，同比减少约44.0%至51.6%;3.经调整净利润将介于约人民币5140万元至5930万元，同比减少约43.1%至50.6%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1141":"生命科学工具和服务","03880":"泰德医药"},"translate_title":"Tide Pharmaceuticals (03880) issued a profit warning, expecting first-half profit to decrease by about 44% to 51.6% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":1.5},"content_text":"智通财经APP讯，泰德医药(03880)发布公告，相较于截至2025年6月30日止六个月的数据，董事会预期截至2026年6月30日止六个月：1.收入将介于约人民币2.298亿元至2.392亿元，同比减少约5.7%至9.4%;2.利润将介于约人民币4940万元至5710万元，同比减少约44.0%至51.6%;3.经调整净利润(非国际财务报告准则计量)将介于约人民币5140万元至5930万元，同比减少约43.1%至50.6%。该等业绩变动主要归因于以下综合因素的影响：1.收入确认的时间性差异：部分客户订单的交付及收入确认预计将延迟至2026年下半年，导致中期收入阶段性减少。2.利润下降的主要原因：(i)集团若干现金及现金等价物以及贸易应收款项以美元计价。期内人民币升值导致账面取得外汇损失，对利润产生负面影响;(ii)非经常性收益消失：2025年中期利润包含一笔因赎回负债于公司上市时转换为权益而产生的以公允价值计入损益的金融负债的公允价值变动所产生的非经常性收益。此乃一次性项目，于2026年中期不再发生;(iii)销售收入同比下降，导致毛利额下降。董事会谨此强调，上述中期业绩波动并未影响集团的核心业务实力及长期发展前景。随着与客户的合作持续深化及其管线进展，集团于2026年7月成功获得海外客户一笔大额订单。该订单强化了集团的订单储备。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}